Mild psoriasis as a suitable model for proof‐of‐mechanism in a phase 1B setting: Results from a double‐blind placebo‐controlled trial with guselkumab
British Journal of Clinical Pharmacology · 2025
DOI: 10.1002/bcp.70179 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift British Journal of Clinical Pharmacology, 2025. Verfasst von Jannik Rousel und 11 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Human Drug Research, Leiden, the Netherlands. Hauptthemen laut MEDLINE: Psoriasis, Antibodies, Monoclonal, Humanized, Dermatologic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Janssen-Cilag B.V., Toegepaste en Technische Wetenschappen, NWO, Janssen Pharmaceuticals.
Abstract (Originalsprache)
Aims
Early clinical development of novel psoriasis therapies is hampered by a decreasing number of moderate‐to‐severe psoriasis patients eligible for participation in trials since efficacious treatments, such as biologics, have become widely available. The aim of this study was to establish mild psoriasis patients as a suitable alternative trial population since these patients are generally not eligible for these treatments.
Methods
A randomized double‐blind controlled trial was performed in 20 mild psoriasis patients (psoriasis area and severity index ≤5), randomized 3:1 to guselkumab 100 mg or placebo, and 5 moderate‐to‐severe psoriasis patients (psoriasis area and severity index ≥10) on guselkumab 100 mg. Clinical scoring was performed over 24 weeks and substantiated with multimodal imaging comprising multispectral imaging, optical coherence tomography and laser speckle contrast imaging.
Results
Clinician‐reported outcomes demonstrated significant treatment effects compared to placebo in mild patients. Focusing on a target plaque, severity scores significantly decreased during treatment with guselkumab only. Imaging demonstrated significant decreases in erythema, maximal height within‐lesion and cutaneous perfusion compared to placebo. Plaques of mild and moderate‐to‐severe patients did not differ at baseline and showed similar treatment responses.
Conclusion
Clinical scoring and multimodal lesion monitoring enabled the detection of a clear treatment effect of guselkumab in mild psoriasis patients. Although this trial was not powered to demonstrate equivalence between the severity groups, our results indicate that the treatment responses follow the same trend in mild and moderate‐to‐severe patients with a high degree of similarity. Therefore, mild patients can be considered a suitable study population for early phase proof‐of‐concept trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre for Human Drug Research, Leiden, the Netherlands.
- Leiden Academic Centre for Drug Research, Leiden University, Leiden, the Netherlands.
- Leiden University Medical Centre, Leiden, the Netherlands.
- Erasmus Medical Centre, Rotterdam, the Netherlands.
ORCID-Profile: Jannik Rousel, Tessa Niemeyer-van der Kolk, Robert Rissmann
Förderung
- Janssen-Cilag B.V.
- Toegepaste en Technische Wetenschappen, NWO
- Janssen Pharmaceuticals
Zitieren
APA
Rousel, J., Bergmans, M. E., Bruijnincx, L. J., Lin, S., der Kolk, T. N., Bohoslavsky, R., Yavuz, Y., Klarenbeek, N. B., Bouwstra, J. A., Rissmann, R., van Doorn, M. B. A., & Next‐Generation ImmunoDermatology Consortium (NGID) (2025). Mild psoriasis as a suitable model for proof‐of‐mechanism in a phase 1B setting: Results from a double‐blind placebo‐controlled trial with guselkumab. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70179
Vancouver
Rousel J, Bergmans ME, Bruijnincx LJ, Lin S, der Kolk TN, Bohoslavsky R, et al. Mild psoriasis as a suitable model for proof‐of‐mechanism in a phase 1B setting: Results from a double‐blind placebo‐controlled trial with guselkumab. British Journal of Clinical Pharmacology. 2025. doi:10.1002/bcp.70179
BibTeX
@article{Rousel2025,
author = {Rousel, Jannik and Bergmans, Menthe E and Bruijnincx, Lisa J and Lin, Sissi and der Kolk, Tessa Niemeyer-van and Bohoslavsky, Roman and Yavuz, Yalçin and Klarenbeek, Naomi B and Bouwstra, Joke A and Rissmann, Robert and van Doorn, Martijn B A and Next‐Generation ImmunoDermatology Consortium (NGID), Next‐Generation ImmunoDermatology Consortium (NGID)},
title = {Mild psoriasis as a suitable model for proof‐of‐mechanism in a phase 1B setting: Results from a double‐blind placebo‐controlled trial with guselkumab},
journal = {British Journal of Clinical Pharmacology},
year = {2025},
doi = {10.1002/bcp.70179}
}
EUVIMED